Malignant gliomas are aggressive brain tumors with limited therapeutic options, probably attributed to highly tumorigenic subpopulations of glioma stem cells. Nucleostemin (NS) has been recognized to take part in the self-renewal of glioblastoma stem cells.Aim
The study was undertaken to examine the immunohistochemical expression of NS and explore its correlation with the clinicopathologic features and p53 expression in glioma.Results
The study included 33 cases of glioma diagnosed in Suez Canal University Teaching Hospital between 2010 and 2015. NS expression was observed in 39.4% of the studied tumors, predominantly in glioblastoma, gliosarcoma, and anaplastic astrocytoma (53.8, 100, and 50%, respectively). We observed a significant grade-by-grade increase in NS expression in the studied gliomas using the χ2-test linear-by-linear association (P=0.02). Moreover, the association between NS expression and combined tumor grade was highly significant (P=0.02) as 84.6% of NS-positive gliomas belong to the high-grade (III and IV) tumors. In addition, p53 expression was demonstrated in 48.5% and significantly correlated with tumor histology and grade (P=0.03 and 0.01, respectively). Interestingly, 84.6% of the NS-positive tumors, predominantly of grades III and IV, displayed p53 expression, whereas only 25% of the NS-negative tumors showed p53 immunoreactivity.Conclusion
In view of our results, we assume that NS might play a relatively important role in the progression of glioma. Further studies in larger cohorts are warranted to elucidate the pathways coregulated with NS in glioma, in particular, those expressing mutant p53.